Facts? Yeah...tell me all about them. I'm all ears.

Holla

M$

A warranted post regarding two Algernon Pharmaceuticals screenshots on its website (before their website was recently revised) of a "Speculative Buy" opinion by independent investment advisor Christopher Temple. Temple is a popularly known and federally convicted fraudster, and neo-Nazi.

Click - "Watch on YouTube" - link in black box above.

Where does Algernon Pharmaceuticals truly stand on critical issues, be it monetary investment or otherwise, of the day?

It's your money invested in people not products at this stage of the process.

Just facts,

M$

All I'm saying is you're make stuff up. As I've said many times before I'm following the nightmare story to it's conclusion. What's changed about that? I'll tell you...not a damn thing.

Holla @ me

M$

Not even a drop in Bucket more like a drop in thimble

AGN/PF = 727,537,885 Outstanding.

AGN Neuro = 900,000,000 Outstanding.

Warrants Are Well North Of 1 Billion Combined.

Alpha North Management Probably Has A Hold Of Everything Combined Upwards Of 20%.

Algernon Pharmaceuticals Will Never Uplist To NASDAQ.

It Was The Reason You Were Given For All Of The Stock Split Activity.

If you Rounded Everything To 3 Billion Shares, How Much Would The Market Cap Need To Be To Break Even @ $7.50 USD Per Share?

Insert Jeopardy Game Show Music Here:
~~~~~~~ ~~~~ ~ ~~~~~.

One Contestant Answered:

"Fool Me Once...

Fool Me Twice..." - G.W. Bush

RIP ~ Alex Trebek.

Holla @ me

M$

IMO, you're grasping at straws at this point

nothing is 100% in the breathalyzer space

adversarial for adversarial sake

makes no sense or dollars

peace

M$

Excerpts from the latest filed MD&A:

Algernon Pharmaceuticals Inc.
MANAGEMENT’S DISCUSSION AND ANALYSIS
For the six months ended February 28, 2023
Dated April 28, 2023

1) Marketing expenses were $887,458 for the six months ended February 28, 2023 (2022 – $266,965). The increase from the six months ended February 28, 2022 resulted from additional marketing activities being performed during the six months ended February 28, 2023, including the Company being the headline sponsor for the 2022 Wonderland Psychedelic Conference in November 2022. Additional promotional activities were performed during the six months ended February 28, 2023.

2) LIQUIDITY AND CAPITAL RESOURCES

Liquidity risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due. The Company manages its liquidity risk by forecasting cash flows from operations and anticipated investing and financing activities. The Company’s objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements.

At February 28, 2023, the Company had a working capital deficit of $1,970,610 compared to working capital at August 31, 2022 of $310,999. This included cash and cash equivalents of $220,585 (August 31, 2022 - $1,408,509) available to meet short-term business requirements and current liabilities of $2,447,732 (August 31, 2022 - $2,516,099). The Company’s accounts payable and accrued liabilities have contractual maturities of less than 30 days and are subject to normal trade terms. The Company has no long-term debt.

At present, the Company has no current operating income. The Company will need to raise sufficient working capital to maintain operations. Without additional financing, the Company may not be able to fund its ongoing operations and complete development activities. The Company intends to finance its future requirements through a combination of debt and/or equity issuance. There is no assurance that the company will be able to obtain such financings or obtain them on favourable terms. These uncertainties may cast doubt on the Company’s ability to continue as a going concern.

Full stop

Ya Think The Decision To Continue Prancing Around Penny Land Like A Peacock With Your "Marketing" Money Is Worthy Of A Feather In The CEO's Cap? Monies You Clearly Do Not Have To Waste That's Targeted At Propping Up The "Privately" Traded Subsidiary AGN Neuro?



Any Of You Own Direct Shares Of AGN Neuro or Just Sitting On The Sidelines Hoping Yet Another Disaster Does Not Unfolded To The Tune Of 90% Plus Losses Across The Checker Board?

Meanwhile, Companies Like Bellus Health (NASDAQ: BLU), Bellus Health Was Recently A Two Billion Dollar Buyout Pharma Company That CEO Moreau Has Long Since Tried Tieing A "Competitive Comparison" To It And AGN/PF, Remained Low Key And Data Driven For It's Shareholders. Bellus Health Continue To Be One To Watch As A Lesson On How To Run A Successful And Expeditious Standalone Clinical Trials In The USA Without The Need For Paltry "Tax Rebates" Long After Data Results. The Australian (Land Down Under/Dante's Inferno/Hurry Up And Wait/Purgatory) Clinical Trial angle, IF Chosen Once Again As Part Of A Miserable Marketing Message - "Multinational" Clinical Trial Of It's IFENPRODIL Chronic Cough Angle, And It Will Most Likely Be Yet Another Powergun Nail In The Coffin For Parent Company - Algernon Pharmaceuticals Inc.

Thus, Maybe You should Seriously Consider Buying Direct Shares Of AGN Neuro? It Could Soon Become Your Last Gasp At Recouping Massive Losses From The COVID-19 Era Moving Forward >>>

M$

Outro

Can't Count To 10?



M$

1 Can E Z Lee C A Regular Clown Show @ AGN/PF



No Need 2 Own Any AGN/PF Wolf Tickets.

Like Receiving A Second "My Pillow".

It's Free!


M$

Another Clown Show response by a CEO in over his head in debt and dishonesty. That email is worthy of a trash can. If Algernon Pharmaceuticals ever survives self-inflicted financial troubles, you'll likely hear the same drumbeat to no end about Bellus Health. As you should be keenly aware of by now, none of the money the CEO is currently trying to raise will go towards a standalone Chronic Cough clinical trial. It will go towards trying to keep the lights on in their virtual company offices somewhere in Canada.

You need real world efficacy of a drug (Data Driven) to prove anything worthwhile ($) in pharmaceuticals. Bellus Health methodically went about the business of doing just that for their shareholders. they didn't spend years wasting money and time chasing rabbits down hellholes in Pennyland. The CEO offers more Lip Service and Hoping Wishing stuff from one year to the next. He simply wants more of your money to dump into his salary and benefits package. He's been very successful at doing just that ever since Calendar Year 2018.

A Data Driven company Algernon Pharmaceuticals is not. You'll see further glaring evidence of that when they pigeonhole another clinical trial in slow roll enrollment rate Australia for "Tax Rebates" received many years later Those at the helm of Algernon Pharmaceuticals are cut from the cloth of Penny Stock operators, through and through (Like The Wolf Of Wall Street). Period.

More Wolf Tickets



M$

P.S. I am not a subscriber of anything coming from Algernon Pharmaceuticals. Thanks for the Heads Up Shell.

Max2121 stated:

First off, I do not profess to know more about "drugs" than anyone here or the World Wide Web.

Second, we are on the same page.

I have not "compared" Bellus Health to Algernon Pharmaceuticals Inc.

This is what I said:
It's the "CEO" of Algernon whose consistently made such a comparison to Bellus Health.

Point the finger(s) at Christopher Moreau (CEO @ Algernon Pharmaceuticals Inc.) not at me or anyone else.

I also listed a litany of historical fumbles and bumbles (I could list a 100 more E Z) at the hand of Christopher J. Moreau (CEO) since taking control of Algernon Pharmaceuticals Inc (formerly Breathtec Biomedical Inc) - Circa 2018. Over 5 years ago!

I'd be fascinated to see/read any serious counter argument to any of the Bullet Points I laid out in E Z LEE understood terminology.

Bulletproof



Hav @ It

M$

ALL-TIME TOP 10 POSTERS @ BLOZF

1) shell3
2) Money $hot
3) Carthnel
4) smoki
5) GOLD DIGGAA
6) medchem
7) SO75
8) euroconversions
9) RolandDoe
10) FreezeThese

Reservoir Dogs



Recognize,

M$

I EVOLVE

OLD DOG



Hav @ it

M$

I have zero idea or thought or care whether or not "news" (+/-) is coming soon. What I always care about is - F A C T S. Shell laid some out in a way that's E Z 2 Understand and makes for a good argument moving forward as to the viability of a roadside Marijuana Breathalyzer being a key component to future Drug Screenings. Without the "IMPAIRMENT" only piece of the equation, I would continue to stand on the belief Cannabix's breathalyzer technology will go no further than testing, testing, and more testing. The addition of a roadside device specifically targeting IMPAIRMENT is the exact type of Artificial Intelligence (AI) that can/will likely move ALL drug screenings into The Next Millennial & Beyond >>>

Just 1 Opinion,

M$

Yo Cart!

It's not hard to get the name right.

Money Shot

"PURE COMPETITOR" BELLUS HEALTH EXPLODES TO UPSIDE

Market Cap Closing In On USD 2 BILLION @ 14.50 per share

https://www.calm-studies.com/#!/

It's Algernon Pharmaceuticals "CEO" who've long since made a comparison of Algernon Pharmaceuticals to what Bellus Health has flawlessly executed in the Chronic Cough area of disease.

It's Algernon Pharmaceuticals "CEO" who sat on the companies best possible chance out the gate (2018/2019) for ALL shareholders to have prospered from the acquisition of it's lead drug IFENPRODIL for Chronic Cough.

It's Algernon Pharmaceuticals "CEO" whose to date still not positioned the company to begin running a standalone Chronic Cough clinical trial for - Yea or Nay - Proof IFENPRODIL is effective at treating Chronic Cough.

It's Algernon Pharmaceuticals "CEO" who told the general public that pursuing Idiopathic Pulmonary Fibrosis was/is a more lucrative route to take for a fledgling pharmaceutical company.

It's Algernon Pharmaceuticals "CEO" whose spent ALL The Money chasing the latest Hot Headline (COVID-19, DMT...) in Pennyland, down a Deep, Dark & Twisted Rabbit Hole, likely to another disastrous conclusion.

What Percentage Of Success (POS) does the "CEO" place on DMT @ Phase 1 or 2...?

It's Algernon Pharmaceuticals "CEO" who spent years kissing the behind of one Kulwant Malhi (King Penny Flipper), and flushing shareholders best interest down the toilet.

Conflicts Of Interest...What Conflicts Of Interest? Who ME ("CEO")?

It's Algernon Pharmaceuticals "CEO" who finds himself at the helm of a company on life support as it tries to raise chump change to keep the lights on @ it's Virtual Offices somewhere throughout Canada.

It's Algernon Pharmaceuticals "CEO" who is counting on YOU to simply let by bygones be bygones, and he's onto bigger and better things for the company, you, and the world at large.

How In The World Algernon Pharmaceuticals "CEO" remains at the helm remains an overwhelming bonkers thought.

Only In Penny World could you tell a story like ^that with a straight face.

STR8 FACE



M$

Yo X! L I F E

Get A Grip On It!

I'm in agreement with Shell regarding the combination use of the IMPAIRMENT device and Cannabix's DRUG DETECTION device (THCBA) working in tandem. The other company seems to have a well polished deliver of information system in place. That IMPAIRMENT TESTING video is top shelf stuff.

As to whether or not any of it translates to commercialization remains a spectacular hurdle IMO. Laws of the land would still need to fall into place for all involved to build out a broad network of distribution and services. Maybe even a global network?

Meanwhile, I'm not one to make any speculative bets on the stock price one way or another. Those days went out the window way back in 2016/2017 when Cannabix's story about imminent commercialization in Canada flew out the window of opportunity.

Fool me once...

Fool me twice...

Shame
Shame
Shame

M$

The Legalese For Saying Screw You USA

Hell, Grand Cayman, Cayman Islands



If you are with the Cayman Islands Crew buying in on the dirt cheap every go around (2 BILLION SHARES IN TOTAL ISSUED WHEN YOU FACTOR IN ALL THE HISTORICAL STOCK SPLITS, WARRANTS, RSU's, "PRIVATE" SUBSIDIARY GIBBERISH, YADA YADA YADA), well it's no skin off your back to pony up a couple dollars out of your Golden Parachute Sack.

Here's an IDEA (Light-bulb). How about management move the company from Canada to America?

Shareholders underwater can name Algernon Pharmaceuticals next parade through pennyland...the YOU HAVE THE RIGHT TO REMAIN SILENT roadshow.

It's A Karaoke Style - Song & Dance Along - Until The Plug Gets Pulled

&

Christopher J. Moreau (CEO) Gets Permanently Yanked Off The Stage

By Hook Or By Crook






























Oh Look! The Weeknd Is Here Already:



M$

Please escort me to the Wood Chipper if my pattern of posts @ AGNPF are wantonly reduced to trolling the message board.

The MindlessVerse



M$

IMO, consistently filling in some of the blanks here (AGNPF), there (AGN), and seemingly everywhere all at once remains a noble cause.

Also, "Parroting" falls into a category of words like Paltry and Pathetic.

Truth is what...Truth?

Is Truth Finite or Infinite?

Multiverse



It's Your World!

Hav @ it

M$

I'm looking forward to reading ALL the wonderful, whimsical, thought provoking, and poetic pontifications when AGNPF crosses below USD 10 CENTS.

M$

Truth is...be it considered exciting or boring to the reader...truth is always a good premise to offering any post.

If Algernon Pharmaceuticals cannot raise the paltry sum of money they're simultaneously requesting from multiple sources (AGN/PF, AGN.RT, AGN Neuro), simply put, their goose is cooked.

Facts matter,

M$

tcm55 posted - US can buy Neuro only shares @$.73

Truth is - US can Neuro only shares @ $1.00


tcm55 posted - So, buy into the new plans or be diluted.

Truth Is - Dilute your current shares buy buying more shares @ $1 versus at market .20 cent.


tcm posted - Speculative investing in the only real medical DMT (microdose) use seems for stroke rehab, with an IPF future for Ifenprodil.

Truth Is - There's plenty of DMT (microdose) deals out there:


- Small Pharma

- GH Research

- MindMed




smoki posted - "...fool to buy into that deal."

Truth Is - All the above is the real deal.


The #1 asset of Algernon Pharmaceuticals since the inception of it's "Repurposed Drugs" scheme in 2018 (post Breathtec Biomedical name change) remains Ifenprodil for a stand-alone Chronic Cough clinical trial. It was their best chance to propel the prospect of profits before dilution from 40 Million fully adjusted shares to effectively 2 Billion fully adjusted shares.

Instead, Algernon Pharmaceuticals blew a legitimately E Z shot on goal right out of the gate back in 2019. It's been a revolting ride through a man-made hellhole for any shareholder whose not an insider or privy to insider information of the past 5 Years (Insiders, Fam, Friends, Offshore Cayman Island Account Holders, Biopub Subscribers, Kulwant Malhi/King Penny Flipper, Other Known/Unknown Participants).

ALGERNON TO DA MOON !!!



M$

Follow up: Miraculins Inc.

"The board recognizes and appreciates James Kinley's contributions and dedication in his role as CFO over the past four years and we wish him well in the future," said Harry Bloomfield, Chairman of the Miraculins board.

https://www.accesswire.com/435700/Miraculins-Announces-the-Appointment-of-Chris-Carmichael-as-Chief-Financial-Officer

Muraculincs changes to Luminor Medical Technologies.

https://www.newsfilecorp.com/release/33402/Luminor-Medical-Technologies-Changes-Its-Name-to-RISE-Life-Science-Corp.

Luminor Medical Technologies Changes Its Name to RISE Life Science Corp.

"Mr. Bloomfield's insights during his tenure as Chairman, helped to significantly move the company forward." said Anton Mattadeen. "We wish to thank him for his leadership."

Britannia Completes "Go Public" Transaction via Reverse Takeover of Rise Life Sciences and Launches Britannia Life Sciences Inc.

https://www.newswire.ca/news-releases/britannia-completes-go-public-transaction-via-reverse-takeover-of-rise-life-sciences-and-launches-britannia-life-sciences-inc--890705573.html

Miraculins to Luminor to Rise to Britannia

Full Stop

Algernon Pharmaceuticals Announces Appointment of Harry Bloomfield, QC. as a New Board Director and Chairman

September 9, 2021

“The Company welcomes Harry Bloomfield as its newest Board member and Chairman,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “His extensive background and years of experience in senior business roles will be a tremendous asset to the Company as it moves forward executing its exciting and unique drug repurposing business plan.”

https://finance.yahoo.com/news/algernon-pharmaceuticals-announces-appointment-harry-110000362.html

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has appointed James Kinley as its chief financial officer, effective December 1, 2021.

Kinley will report to CEO Christopher Moreau, according to a statement.

"James Kinley brings significant functional expertise and technical knowledge to the company in all aspects of corporate finance, financial planning and accounting,” said Moreau.

https://www.proactiveinvestors.com/companies/news/967761/algernon-pharmaceuticals-appoints-former-medicure-financial-chief-james-kinley-as-cfo-967761.html

Leadership @ Algernon Pharmaceuticals Inc.

Harry Bloomfield, Board of Directors, Chairman

Christopher J. Moreau, CEO

James Kinley, CFO

Three Headed Monster In Black & White



The Devil Is In The Details...

And It's Headed For The Trips (.0001)

Hav @ it

M$

No worries...your CEO has been down this road before.

You'll lose all your shares of Algernon Pharmaceuticals.

You'll get whatever allotted number of shares held from Algernon Neroscience.

There'll be a massive consolidation of Algernon Neuroscience.

An Uplist back to the penny stock exchanges will be imminent.

MOREAU'S ROAD MAP IN DANTE'S INFERNO

Miraculins Announces Name Change, New Stock Symbol and Share Consolidation
Wednesday, April 13, 2016 8:08 AM

https://www.accesswire.com/438746/Miraculins-Announces-Name-Change-New-Stock-Symbol-and-Share-Consolidation

M$

News Release - Reveals 440% Markup For USA Buyers


Apples (Rights Offering at 25 Cents CAD per share.

Versus -

Oranges (US offering at 1 Dollar USD per share).


^That's 1.10 CAD more per share for any current or would-be USA investor willing to take a bite of a targeted New York Apple.

The more foot dragging transparency Algernon Pharmaceuticals welcomes, the more disdain is revealed for USA shareholders.

Crazy Is As Crazy Does.


Rotten Apple


M$


Outro

De La Soul

M$

For Your Viewing Pleasure:

algernonneuroscience.com/board-of-directors/

Would you look at that...everyone has a photo.

It would appear in comparison to the parent company website...they all chose to come out of hiding.

M$

Today: Anyone got any Tea to spill?

Yesterday: AGN.RT Volume 0 (Zero).


The rubber meets the road.

The hot air now runs flat.

No spare room for false-hood.

Never get tired of the facts, Jack.


The Rabbit Hole




M$

Ladies and Gentlemen of the United States of America, please do not be fooled.

Rights Offering

Rights Offering - Page 11:

https://webfiles.thecse.com/1._Algernon_-_Rights_Offering_-_Circular_2023.pdf?ud7uis0JjvyOX5Wavb6jLIdFVUZlQ0wX

The above was highlighted in red to point out a clear fact without dispute.

Full Stop


Thus, one must question if people have actually read/understand the "Rights Offering" as written in black and white?

If they have read/understand the document, from what other source did anyone receive information contrary to what's written inside the four corners of the Rights Offering?

USA shareholders will swiftly lose up to 50% of their current stock equity as a direct result of the Rights Offering.

Period


OAN: There is absolutely no disputing Algernon Pharmaceuticals endorsed a neo-Nazi's (Christopher Temple) investment opinion on their corporate website.

Christopher Temple is also a convicted felon who spent 6 years in federal prison for swindling investors out of millions of dollars.

^That's the "measure of a man" Algernon Pharmaceuticals is willing to publicly endorse with your money.

But for Algernon's sheer boldness to endorse a MONSTER OF HATE for their own meager and ineffective purposes, I would not have returned nearly 6 months later to this USA message board or Canadian message board.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169424184

Someone, somewhere within an arm's-length of Algernon Pharmaceuticals smelly deeds, needed to stand up against such an insane and insensitive decision without fear or favor.

If you cannot air out these types of troubling issues directly relating to your investment decisions on forums such as Investorshub, we are all doomed.


M$

Maryland considers new marijuana impairment detection devices for drivers

https://www.wusa9.com/amp/article/news/local/maryland/maryland-marijuana-detection-device/65-f3752b2f-f4bd-438b-8678-11ddbe847e7c

https://www.cognivue.com/

https://www.cognivue.com/wp-content/uploads/2020/04/Cognivue-Clarity-2.jpg

The problem with Cannabix's technology is it doesn't target IMPAIRMENT. That's the exact same angle as Hound Labs so-called marijuana breathalyzer. The technology that's discussed in the article does target IMPAIRMENT. That will most likely be the deciding factor for any marijuana device being court approved along with laws that have yet to be written and/or enacted.

Simply listen closely to what the reporter in the video states. He's 100% on point with the challenges ahead for an effective roadside device for law enforcement. IMO, Cannabix's best shot at monetization is it's contactless BAC device(s) for the workplace and vehicle. However, it doesn't appear to be a novel invention stopping the masses from gobbling up market share if ever proven to be a viable revenue stream.

Meanwhile, testing remains the foreseeable future forecast at Cannabix as it has been the past 8 years...

Cloudy.

M$

The past track record of Algernon Pharmaceuticals is clearly more relevant than a stock trade involving Google that someone may or may not have executed back in 2000.

There is nothing about Algernon Pharmaceuticals (USD 2.65 Million ($2,650,000) Market Cap) even remotely part of the same investment conversation/comparison as a company like Google (USD 1.36 Trillion ($1,360,000,000,000) Market Cap).

However, if anyone truly believes Algernon's past is not relevant, I'll further clarify "what's happening right now or not."


What IS NOT happening right now...

Algernon Pharmaceuticals IS NOT actively conducting ANY clinical trials for any of the following diseases it parrots to the public.

- Idiopathic Pulmonary Fibrosis (IPF)

- Chronic Refractory Cough (CRC)

- Nonalcoholic Steatohepatitis (NASH)

- Small Cell Lung Cancer (SCLC)

- Pancreatic Cancer

- Chronic Kidney Disease

Algernon Pharmaceuticals clinical trial pipeline is Dead In The Water.


What IS happening right now...

- MASSIVE DILUTION by 100% and 200% clips at a time.

The creation of a subsidiary company "Algernon Neuro" has issued 20 million privately held shares plus warrants. That's double the current number of AGN/PF shares.

Further still, the recent creation of a "Rights Offering" exclusively for Canadian shareholders has created another 10 million shares plus matching warrants.


What IS happening right now…

Shareholders are being eaten alive as Algernon Pharmaceuticals hopes and wishes that DMT will save the company from bankruptcy.

Dr., Professor David Nutt (Algernon Neuro advisor) gives the DMT angle a generous 30% Chance Of Success.

All your Easter Eggs are basically in one basket whose destiny is dependent on a private company (Algernon Neuro) that doesn't report directly to you.

What you receive as accountability from Algernon Neuro is Moreau spending what little money you have on ineffective marketing outlets.

Does anyone following this message board own any shares of Algernon Neuro?

I suspect if Algernon Pharmaceuticals (AGN/PF) survives the next 12 months it will come at the expense of 100 million outstanding shares, not including the shares/warrants at Algernon Neuro.

Pain is the past and present performance measure utilized by your leaders at Algernon Pharmaceuticals Inc.

The more pain they inflict the richer they get.


It IS quite the Rabbit Hole.



Of note: When, not if, AGNPF closes below 25 Cents, it will effectively be trading under 1 Cent (.01) based on a revised 25:1 Reverse Split (100:1 Reverse Split + 4:1 Forward Split).

If you add the previous 2:1 Reverse Split, it's already trading at half of 1 Cent (.005).

A Penny For Your Thoughts?


M$

What I post comes from historical Due Diligence. Who needs to try manipulating a downturn? The CEO at Algernon Pharmaceuticals is doing a bang up job of pushing the stock further into the depths of hell (Dante's Inferno) all by his lonesome. I'm just telling the story as I see it unfolding. If one methodically follows the math of Algernon's separate, unequal, and rapidly expanding trading platforms (AGN/PF, AGN Neuro, AGN.RT), it wouldn't be difficult to understand the combined and ever-changing numbers. It'd be interesting to see if anyone else anywhere has numbers explaining otherwise.

Otherwise _____________.

Does anyone here believe that by increasing the share count with massive dilution somehow will increase the share price? For goodness sake...with all the previous pie in the sky talk about uplisting to NASDAQ, your leaders are now selling your company out from under your feet for 25 Cents Canadian. That's 18 Cents USD not including matching warrants. What you can surely expect moving forward is more(au) monkeying around with coffer draining ($$$) - non performance driven - Salaries, Ferrari size Bonuses, Free stock giveaways, and ineffective big ego feeding "Marketing".

The headliner "2022 Wonderland Psychedelic Conference" comes to mind. How'd that work out for your bottomline?

I have a theory. Maybe it takes a true exit from Dante's Inferno to be capable of explaining a Scorched Earth experience without fear or favor? Then again, personally I've always called it how I see it.

On Another Note:

The last report by stock analyst Dr. Andre Uddin at Research Capital (aka Smackie Mackie), he stated AGN is a $25 CAD per share "Speculative Buy" based on the Idiopathic Pulmonary Fibrosis (IPF) data not the Chronic Cough data.

In the near term, parent company Algernon is not actively pursuing IPF. They're not actively pursuing CKD. They're not actively pursuing Cancer. They're hoping to get funding for a standalone Chronic Cough study as the DMT stuff hangs in the balance. It begs the question of where does Uddin's analysis stand now considering all of Algernon's flip flopping since his last analysis back in July 2022?

Split adjusted, Uddin's buy rating is $6.25 CAD/$4.50 USD per share. It doesn't get the 100:1 pre-split shares to a minimum break even price of $7.50 USD.

My best guess is Uddin will not update his analysis anytime soon. To date, none of his AGN buy ratings have been accurate. However, I give him credit for telling the truth about Algernon's failed COVID-19 Topline data (ZERO Efficacy). It was data the CEO (Moreau) continued to pump/pedal and refuse to admit it was a failure.

In contrast, Uddin stated in black and white that Ifenprodil would not advance to a Phase 3 clinical trial and that's Egg Zack Lee what happened irrespective of Moreau jumping up and down for several months thereafter as if a Phase 3 COVID-19 clinical trial was imminent.

Would Algernon Pharmaceuticals care to share their FDA "End of Phase 2 Meeting Request" findings with all shareholders? Let's see (in black and white) how it aligns with the CEO's reasons for not advancing Ifenprodil to a Phase 3 clinical trial.

Ifenprodil was convincingly labeled a "65% Chance Of Success" by your CEO (Christopher Moreau) and CSO (Dr. Mark Williams, PhD, MBA). If only they had conjured up some mathematical magic for Ifenprodil having a 100% Chance of Success, WHO KNOWS, Algernon's market cap may have topped a GAZILLION DOLLAR$?

Algernon Pharmaceuticals Inc - Home Of The Wizards Of Odds




M$

The next move to move where...back to 40 or 50 cents tops? Lots of stuff not only sound like a broken record, but it truly is a broken record. The name of Cannabix's tune is called - Happy Flipping. It's a hit record on the historical chart.

M$

Let's put the "Trust" and "Confidence" theory to a test.

Trust is the belief that the person to be trusted would act as the trusting person would in that situation.

Confidence is related to factors such as competence or past performance.

Trust builds Confidence.

Thus far, Moreau (CEO0 started out with 40 million shares of Breathtec Biomedical. Those shares have since turned into 4 billion split adjusted Algernon shares. I've previously laid out the math.

A 100:1 reverse split happened due to the CEO begging shareholders to believe him that a Nasdaq uplisting was necessary and imminent for the company's survival. Wall Street experts gave Algernon Pharmaceuticals a resounding vote of NO CONFIDENCE.

The COVID-19 clinical trials were diversions/excursions from the targeted pipeline and secured massive dilution right out of the gate for shareholders - the covid scheme coughed up more than 100% dilution for two demonstrably failed studies in South Korea and Romania.

The CEO abandoned the FAIMS technology after stating in black and white the program would continue irrespective of having gone down the repurposed drugs path. He back peddled on that claim shortly thereafter.

By the way, that FAIMS “Research Only" angle abandoned by Algernon is now being peddled by Cannabix Technologies. The exact same FAIMS technology advanced by the monetary partnership ($$$) between Cannabix and Algernon will only have one possible winner to the agreement no less credited to Algernon’s haphazard management decisions.

Meanwhile, AlphaNorth (a small Canadian investment outfit) is gobbling up the company right before your eyes. They'll likely own somewhere north of 20% of Algernon in short order. Dilution has been their best friend (BFF) and there’s lots more where that came from friends.

There are now 3 separate and unequal pots of shares (AGN/PF, AGN Neuro, AGN.RT) that attempt to camouflage the insane amount of dilution since the 100:1 reverse split. It's been a 300% increase in shares since ^that split.

There are ZERO known plans to raise capital for ANY clinical trial for Algernon Pharmaceuticals. Keep in mind, there are no clinical trials being conducted by Algernon. The only trial happening is a Phase 1 at the "Private" subsidiary company for DMT.

What you are getting beyond dilution is Moreau prancing and dancing around clown town spouting about DMT. That is all.

Moreau also encouraged you to buy shares of the "private" company. That doesn't project confidence in the direction of AGN/PF shares.

They are struggling now to keep the lights on at their virtual corporate office but their salaries and bonuses have not suffered or sacrificed in the least bit.

No one has disputed any of the math.

No one has disputed the fact Moreau endorsed neo-Nazi Chris Temple's "Immediate Buy" opinion of the stock 6 months ago. Chris Temple is a neo-Nazi wearing black suspenders with a Nazi logo. He's standing directly behind the neo-Nazi leader carrying the American flag.

https://investorshub.advfn.com/uimage/uploads/2023/3/25/qkqylChris_Temple_-_neo-Nazi.jpg

^This is not a personal attempt to offend anyone here. It’s an attempt to make you aware of the type of reckless decisions being made by a publicly/globally traded penny stock company. You deserve the right to know. If Algernon management doesn’t want you to know what they stand for or against, they should take the entire company private. It seems to be headed in that direction anyway as time rolls bye bye.

No one has disputed the fact Algernon's CEO (Moreau), CSO (Williams), CFO (Sadhra) ALL orchestrated a blatant, and should be criminal, conflict of interest by working for Kulwant Malhi at failed (bankrupt) First Responder Technologies. Malhi was flipping shares of AGN/PF by the millions and walked away with somewhere around 10 Million Dollars at the time shareholders were losing all their money with falling stock prices that never recovered.

The above is merely a handful of "Trust" and "Confidence" issues.

A proclaimed buy-in of AGN.RT by anyone means they're a Canadian investor. The news flash here is - most are not eligible to participate in this latest dilution scheme.

The price of the "Rights Offering" shares are equal to 18 cents with a matching warrant.

Shares of AGNPF (USA shareholders) would need to trade at 9 Cent to match the Rights Offering by Algernon Pharmaceuticals Inc.

It would appear that sub 10 cent shares of AGNPF is not out of the realm of possibility.

If you took the closing price of today's Market Cap and divided it by the true number of outstanding shares, this would be the true price of all the shares:

AGN/PF - 10 Million shares

AGN Neuro - 20 Million shares

AGN.RT - 10 Million shares

Total Shares - 40 Million

Algernon Pharmaceuticals Inc - Market Cap $2,658,000

Divide the Market Cap by 40 Million.

2,658,000/40,000,000 = 6 Cent

6 Cent (.06) is where the true price of all shares should fall.

All ^that and I didn't even mention the "Trust" and "Confidence" 55% and 65% Chance of Success claims pumped to the masses with Biopub webinars.

Hey Mag...how about that PPCB? See any type of "Trust" or "Confidence" comparisons to AGN/PF?

Maybe it all depends on where one's time and money fits into the narrative in order to see the entire picture versus a snapshot huh? What I've stated here barely scratches the surface of Algernon's man-made Dante's Inferno.


AGN/PF Splits

Oct 17, 2018 - 2/1 Reverse Split

Nov 24, 2021 - 100/1 Reverse Split

Mar 3, 2023 - 4/1 Forward Split


Minimum Break Even Share Price

$7.50 USD

As I’ve stated before, by the time Algernon gets to any significantly compelling data, the Market Cap may require a Multi-Billion dollar valuation for Reverse Split shareholders to break even, if ever.

On Another Note...without getting too long-winded, I’ll drop that one here tomorrow (Sunday).


M$

You, Me, and Shell3. We go back to the beginning here. Alpha Dogs! In that time, there is nothing that kept me on this message board more than gaining Truth and Understanding. I never understood how the people running this company from Breathtec Biomedical to Algernon Pharmaceuticals and its subsidiaries could never get their act together on behalf of shareholders. They have lied manipulated and ripped off shareholders from the beginning into the foreseeable future.

Never before and never again will I ever get tricked and ripped off by another penny stock company. These people will drag you through the depths of hell (Dante's Inferno) endlessly if you let them. They're all rich and getting filthy richer at your expense and the grift will continue until they've burned through every possible avenue to keep it afloat. In my opinion, short of eternal damnation a jail cell is too good for those at the helm. I truly believe they have no souls.



I also don't do things to lose a small fortune.

It wasn't by fate. It was by fraud.

Peace

M$

It's Actually 2 Billion Outstanding Shares Now - Split Adjusted

2:1 Reverse Split

+

100:1 Reverse Split

+

4:1 Forward Split

=

50:1 Reverse Split
_________________

Now take all the current oustanding shares and times (x) it by 50.

AGN/PF 10,000,000 Shares

AGN Neuro 20,000,000 Shares

AGN.RT 10,000,000 Shares
__________________

That's a total of 40,000,000 Shares times 50 equals 2,000,000,000.
__________________

TWO BILLION SHARES
__________________

Matching Warrants...

ADD ANOTHER TWO BILLION SHARES
__________________

Your "CEO" Moreau came in the door and in 4+ years turned less than 40 Million shares into 4 Billion shares with no end in sight other than bankruptcy.

Just facts,

M$

Reverse/Forward Split Adjusted Math



Billions more Split Adjusted Shares are needed to pay for a standalone Chronic Cough study. Meaning, massive dilution (upwards of 4 times more) is in the future if not bankruptcy.

The latest "news release" validates my previous post as it does many of my other posts. How about that AlphaNorth gobbling up the company right in front of your eyes? You are being eaten alive.

There are now 3 separate and unequal tiers of traders - AGN Neuro, AGN.RT, AGN/PF. AGN/PF shareholders are on the bottom rung of ownership. It's your money that supports the others while Moreau runs around Clown Town like a Peacock ranting about DMT.

Have they no shame?

Fool me once...

Fool me twice...

M$

Can anyone point to their "Algernon Neuroscience" share count on paper? It'll be quite interesting to see how all the polluted and diluted math works out in the end. However, if past is prologue one should expect to get shafted the same as every prior mathematical move by Moreau.

I surely would give ^that GLOOM & DOOM scenario a Moreau's Mathematical 55% to 65% chance of success.

Figures don't lie but liars do figure.

Go figure!

M$

One wonders just how many days weeks months years of "testing" news releases can keep this penny ante stock afloat? Is there yet another endless pump to get newbies to dive into the abyss head first? Or, has the wishing well finally run dry? Cannabix is the epic grift that keeps on giving to the rich and taking from the poor little penny pinchers.

M$

FYI:

Predictmedix announces production of AI-powered mobile application to detect impairment from alcohol and cannabis

Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) has announced the production of its AI-Powered mobile app in conjunction with a portable multi-spectral imaging camera to non-invasively detect impairment from alcohol and cannabis.

The non-invasive solution will be commercialized to serve global law enforcement agencies, transport, and other mobile high-risk industries where impairment remains a significant liability, it said.

Recently conducted studies showed that the screening tool, which screens in under 30 seconds, can accurately identify impaired individuals with a success rate of over 90%.

READ: Predictmedix announces completion of 1,600-person clinical study for Safe Entry's medical device regulatory approval in Indonesia
"We are happy to announce to our shareholders that we are making very good progress with our portable solution for detecting impairment in individuals,” Dr Rahul Kushwah, chief operating officer at Predictmedix said in a statement.

“From our research and discussions with high-level contacts, we believe our product will be in high demand in multiple industry verticals worldwide. In 2021, the drug screening market size was valued at over $5.2 billion with revenue forecasted at over $22 billion in 20302, making this another lucrative opportunity for Predictmedix.

"We look forward to updating our shareholders on further technological and commercial development,” he added.

Although cannabis breathalyzers are still at an early stage of development, alcohol breathalyzers have been reported to have up to a 50% margin of error according to the National Motorists Association.

Impairment from alcohol and cannabis has been an ongoing issue for law enforcement and high-risk industries around the world and current screening are long and costly.

The screening tool uses a multiparametric approach to identify unique and specific features based on facial and speech analysis which are analyzed by AI algorithms, resulting in an unbiased outcome, according to the company.

The multi-spectral imaging camera captures non-visible wavelength data which the AI algorithms extract features that are associated with impairment from alcohol and/or cannabis. AI by nature is self-learning, Predictmedix's algorithms improve as more data is obtained and processed resulting in greater accuracy and speed with time, the company said, adding that the speech analysis component of the solution alone has achieved an impressive accuracy rate in identifying impairment.

Predictmedix recognises the potential this specific use-case has for the end consumer and is currently taking action to preserve the rights and IP of the technology for commercialization efforts and shareholder concerns.

Predictmedix is an emerging provider of rapid health screening and remote patient care solutions globally.

Contact the author at jon.hopkins@proactiveinvestors.com